Compare Stocks: UGRO, MWG, BGMS, and CAPS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGMS Cyclacel Pharmaceuticals	$0.97 -6.7%	$0.91	$0.57 ▼ $10.08	$5.74M	-0.38	42,678 shs	54,051 shs
CAPS Capstone Therapeutics	$0.27 +6.8%	$0.27	$0.23 ▼ $2.07	$3.85M	-1.52	304,804 shs	147,866 shs
MWG Multi Ways	$1.14 +0.4%	$1.30	$1.10 ▼ $6.05	$5.87M	1.21	61,708 shs	1,513 shs
UGRO urban-gro	$1.47 +24.6%	$2.22	$2.02 ▼ $37.00	$1.94M	-2.91	72,011 shs	4.93 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGMS Cyclacel Pharmaceuticals	-6.71%	+6.28%	+9.78%	+10.25%	+97,019,900.00%
CAPS Capstone Therapeutics	+4.69%	+12.49%	+10.24%	-27.00%	-80.14%
MWG Multi Ways	-0.52%	-4.67%	-8.84%	-37.11%	-55.31%
UGRO urban-gro	+24.58%	+17.60%	-16.95%	-75.46%	-85.44%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGMS Cyclacel Pharmaceuticals	$0.97 -6.7%	$0.91	$0.57 ▼ $10.08	$5.74M	-0.38	42,678 shs	54,051 shs
CAPS Capstone Therapeutics	$0.27 +6.8%	$0.27	$0.23 ▼ $2.07	$3.85M	-1.52	304,804 shs	147,866 shs
MWG Multi Ways	$1.14 +0.4%	$1.30	$1.10 ▼ $6.05	$5.87M	1.21	61,708 shs	1,513 shs
UGRO urban-gro	$1.47 +24.6%	$2.22	$2.02 ▼ $37.00	$1.94M	-2.91	72,011 shs	4.93 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGMS Cyclacel Pharmaceuticals	-6.71%	+6.28%	+9.78%	+10.25%	+97,019,900.00%
CAPS Capstone Therapeutics	+4.69%	+12.49%	+10.24%	-27.00%	-80.14%
MWG Multi Ways	-0.52%	-4.67%	-8.84%	-37.11%	-55.31%
UGRO urban-gro	+24.58%	+17.60%	-16.95%	-75.46%	-85.44%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGMS Cyclacel Pharmaceuticals	1.00	Sell	N/A	N/A
CAPS Capstone Therapeutics	1.00	Sell	N/A	N/A
MWG Multi Ways	0.00	N/A	N/A	N/A
UGRO urban-gro	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest UGRO, MWG, BGMS, and CAPS Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/29/2026	BGMS Cyclacel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/20/2026	CAPS Capstone Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/14/2026	BGMS Cyclacel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/2/2026	CAPS Capstone Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/24/2026	BGMS Cyclacel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/17/2026	CAPS Capstone Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
6/11/2026	UGRO urban-gro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/3/2026	CAPS Capstone Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
5/27/2026	UGRO urban-gro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/20/2026	CAPS Capstone Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
5/13/2026	UGRO urban-gro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGMS Cyclacel Pharmaceuticals	$750K	7.14	N/A	N/A	$1.40 per share	0.69
CAPS Capstone Therapeutics	$48.11M	0.09	N/A	N/A	$1.37 per share	0.20
MWG Multi Ways	$44.77M	0.13	$0.47 per share	2.42	$0.71 per share	1.61
UGRO urban-gro	$17.40M	0.11	N/A	N/A	($64.63) per share	-0.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGMS Cyclacel Pharmaceuticals	-$3M	-$4.54	N/A	N/A	N/A	N/A	-51.21%	-44.00%	N/A
CAPS Capstone Therapeutics	-$21.23M	-$3.37	N/A	N/A	N/A	-41.26%	-114.15%	-39.74%	8/13/2026 (Estimated)
MWG Multi Ways	$1.79M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UGRO urban-gro	-$22.10M	-$27.87	N/A	N/A	N/A	-82.11%	-118.44%	-33.76%	8/18/2026 (Estimated)

Latest UGRO, MWG, BGMS, and CAPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CAPS Capstone Therapeutics	$0.12	N/A	N/A	N/A	$20.39 million	N/A
5/20/2026	Q1 2026	CAPS Capstone Therapeutics	-$0.19	-$0.21	-$0.02	-$0.21	$10.80 million	$12.64 million
5/14/2026	Q1 2026	BGMS Cyclacel Pharmaceuticals	N/A	-$0.04	N/A	-$0.04	N/A	$0.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGMS Cyclacel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CAPS Capstone Therapeutics	N/A	N/A	N/A	N/A	N/A
MWG Multi Ways	N/A	N/A	N/A	N/A	N/A
UGRO urban-gro	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGMS Cyclacel Pharmaceuticals	N/A	7.06	5.87
CAPS Capstone Therapeutics	0.79	0.95	0.29
MWG Multi Ways	N/A	1.50	0.45
UGRO urban-gro	N/A	0.05	0.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGMS Cyclacel Pharmaceuticals	23.58%
CAPS Capstone Therapeutics	2.55%
MWG Multi Ways	0.81%
UGRO urban-gro	20.56%

Insider Ownership

Company	Insider Ownership
BGMS Cyclacel Pharmaceuticals	23.75%
CAPS Capstone Therapeutics	39.29%
MWG Multi Ways	N/A
UGRO urban-gro	4.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGMS Cyclacel Pharmaceuticals	14	5.52 million	4.21 million	N/A
CAPS Capstone Therapeutics	38	15.20 million	9.23 million	N/A
MWG Multi Ways	92	5.13 million	N/A	Not Optionable
UGRO urban-gro	100	1.32 million	1.26 million	Optionable

UGRO, MWG, BGMS, and CAPS Headlines

Recent News About These Companies

urban-gro, Inc. (Nasdaq: UGRO) Locks Full Five-Franchise Lineup for Lanka Premier League Season 6; New Ownership Named for Kandy Royals, SC Jaffna Kings, and Colombo Kaps Ahead ...

June 16, 2026 | finanznachrichten.de

Flash Sports & Media (Nasdaq: FLZH) Launches Malaysia T20 League (MT20)

June 16, 2026 | globenewswire.com

urban-gro Rebrands as Flash Sports & Media Holdings

June 15, 2026 | tipranks.com

urban-gro, Inc. Announces Shareholder Approval of Name Change to Flash Sports and Media, Inc. and New Ticker Symbol “FLZH”

June 12, 2026 | financialpost.comF

urban-gro, Inc. Announces Name Change to Flash Sports & Media, Inc. and New Ticker Symbol "FLZH"

June 12, 2026 | quiverquant.comQ

urban-gro, Inc. Announces Shareholder Approval of Name Change to Flash Sports and Media, Inc. and New Ticker Symbol “FLZH”

June 12, 2026 | globenewswire.com

urban-gro Adjourns Special Stockholder Meeting for Lack Quorum

June 3, 2026 | tipranks.com

UGRO: urban-gro, Inc. (Nasdaq: UGRO) Announces Lanka Premier League Season 6 Player Auction Set for June 1, 2026 @ 5:00 AM EDT (2:30 PM Colombo Time)

May 31, 2026 | markets.businessinsider.com

UGRO: urban-gro, Inc. (Nasdaq: UGRO) Announces Lanka Premier League Season 6 Player Auction Set for June 1, 2026 @ 5:00 AM EDT (2:30 PM Colombo Time)

May 31, 2026 | financialpost.comF

urban-gro, Inc. Announces LPL Season 6 Player Auction Scheduled for June 1, 2026

May 31, 2026 | quiverquant.comQ

UGRO: urban-gro, Inc. (Nasdaq: UGRO) Announces Lanka Premier League Season 6 Player Auction Set for June 1, 2026 @ 5:00 AM EDT (2:30 PM Colombo Time)

May 31, 2026 | globenewswire.com

Letter to Shareholders from CEO Bradley Nattrass

May 20, 2026 | globenewswire.com

UGRO: urban-gro, Inc. (Nasdaq: UGRO) Locks Full Five-Franchise Lineup for Lanka Premier League Season 6; New Ownership Named for Kandy Royals, SC Jaffna Kings, and Colombo Kaps ...

May 18, 2026 | markets.businessinsider.com

UGRO: urban-gro, Inc. (Nasdaq: UGRO) Locks Full Five-Franchise Lineup for Lanka Premier League Season 6; New Ownership Named for Kandy Royals, SC Jaffna Kings, and Colombo Kaps Ahead of July–August 2026 Tournament

May 18, 2026 | financialpost.comF

May 18, 2026 | globenewswire.com

urban-gro Delays Quarterly Report Filing Briefly

May 15, 2026 | tipranks.com

urban-gro (UGRO) Secures Temporary Relief As Investors Watch The Bigger Turnaround Story

May 8, 2026 | insidermonkey.com

urban-gro, Inc. (Nasdaq: UGRO) — Sri Lanka Cricket Confirms Lanka Premier League Season 6 Foreign Player Registration to Open 8 May 2026; Tournament to Be Played Across Four ...

May 8, 2026 | markets.businessinsider.com

urban-gro, Inc. (Nasdaq: UGRO) — Sri Lanka Cricket Confirms Lanka Premier League Season 6 Foreign Player Registration to Open 8 May 2026; Tournament to Be Played Across Four Venues in July–August 2026

May 7, 2026 | financialpost.comF

May 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UGRO, MWG, BGMS, and CAPS Company Descriptions

Cyclacel Pharmaceuticals NASDAQ:BGMS

$0.97 -0.07 (-6.71%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$0.92 -0.05 (-5.17%)

As of 07:08 AM Eastern

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Capstone Therapeutics NASDAQ:CAPS

$0.27 +0.02 (+6.76%)

Closing price 08/6/2026 03:59 PM Eastern

Extended Trading

$0.27 0.00 (-0.41%)

As of 07:17 AM Eastern

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Multi Ways NYSE:MWG

$1.14 +0.00 (+0.35%)

Closing price 08/6/2026 03:47 PM Eastern

Extended Trading

$1.14 +0.00 (+0.09%)

As of 06:38 AM Eastern

Multi Ways Holdings Limited supplies a range of heavy construction equipment for sales and rental in Singapore, Australia, and internationally. The company engages in the supplying and rental of new and used heavy construction equipment in the infrastructure, building construction, mining, offshore and marine, and oil and gas industries. It offers earth-moving equipment, such as bulldozers, off-terrain dump trucks, excavators, and wheel loaders; material-handling equipment, such as crawler cranes, rough terrain cranes, scissor lifts, forklifts, boom-lifts, and telescopic handlers; road-building equipment comprising motor graders, vibrating compactors, asphalt finishers, skid loaders, backhoe loaders, hand rollers, and mini excavators; and air compressors, generators, lighting towers, and welding machines. The company was founded in 1988 and is headquartered in Singapore. Multi Ways Holdings Limited operates as a subsidiary of MWE Investments Limited.

urban-gro NASDAQ:UGRO

$1.47 +0.29 (+24.58%)

As of 08/5/2026

urban-gro, Inc. engages in the designing, engineering, building, and integrating complex environmental equipment systems for indoor controlled environment agriculture (CEA) cultivation and retail facilities in the United States, Canada, and Europe. The company provides architectural design, engineering, and construction services comprising pre-construction, cultivation space programming (CSP), architectural and interior design, engineering, integrated cultivation design, owner's representative/construction management, and general contracting services; and maintenance, training, and support services. It also offers facility and equipment commissioning services; gro-care crop and asset protection services, including training services, equipment maintenance services, asset protection program, and an interactive online operating support system for gro-care and client document delivery and project management; and property condition assessment services. In addition, the company provides integrated equipment systems solutions, such as design, source, and integration of complex environmental equipment systems comprising heating, ventilation, and air conditioning solutions, as well as environmental control, fertigation, irrigation distribution, water treatment, and wastewater reclamation systems; and commercial horticulture lighting solutions, rolling and automated container benching systems, specialty fans, microbial mitigation, and odor reduction systems. Further, it offers value-Added Reselling (VAR) of cultivation equipment systems; and strategic vendor relationships with premier manufacturers. It primarily markets and sells its solutions to clients in the CEA that includes operators and facilitators in the cannabis and produce markets; and commercial sectors comprising food and beverage consumer packaged goods companies, healthcare, higher education, and hospitality. urban-gro, Inc. was founded in 2014 and is based in Lafayette, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UGRO, MWG, BGMS, and CAPS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UGRO, MWG, BGMS, and CAPS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UGRO, MWG, BGMS, and CAPS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UGRO, MWG, BGMS, and CAPS Company Descriptions

Cyclacel Pharmaceuticals NASDAQ:BGMS

Capstone Therapeutics NASDAQ:CAPS

Multi Ways NYSE:MWG

urban-gro NASDAQ:UGRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UGRO, MWG, BGMS, and CAPS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UGRO, MWG, BGMS, and CAPS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UGRO, MWG, BGMS, and CAPS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UGRO, MWG, BGMS, and CAPS Company Descriptions

Cyclacel Pharmaceuticals NASDAQ:BGMS

Capstone Therapeutics NASDAQ:CAPS

Multi Ways NYSE:MWG

urban-gro NASDAQ:UGRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools